Meeting
2020 Genitourinary Cancers Symposium
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience.
Authors
Deniz Tural
Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
Deniz Tural , Omer Fatih Olmez , Ahmet Taner Sumbul , Mehmet Artac , Nail Ozhan , Emre Akar , Burcu Cakar , Osman Kostek , Nail Paksoy , Mustafa Erman , Hasan Senol Coskun , Fatih Selcukbiricik , Özge Keskin , Fatma Paksoy Turkoz , Kerem Oruc , Selami Bayram , Ugur Yilmaz , Irem Bilgetekin , Birol Yildiz , Saadettin Kilickap
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 451)
Abstract #
451
Poster Bd #
F18
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.
First Author: Deniz Tural
Poster
2020 ASCO Virtual Scientific Program
A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).
First Author: Peter Schmid
First Author: Ana Oaknin
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre